SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors speculate on an imminent buyout and the 80th trial event, with the community actively discussing potential institutional accumulation and high short-interest dynamics. Sentiment remains highly charged around the potential for a transformative partnership or acquisition driven by the company's oncology platform.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is currently polarizing the community as traders debate its potential as a high-growth fintech underdog versus a manipulated asset prone to heavy selling pressure. While some investors highlight potential margin expansion and platform growth as reasons to accumulate, others express significant frustration with technical resistance levels and perceived correlation risks with broader market volatility.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is gaining significant community attention as investors weigh heavy short interest against potential catalysts, including the company's planned acquisition of LivePerson and expansion into telecom and energy sectors. Enthusiasts are actively tracking technical breakout levels and options positioning, hoping that increased buying pressure will trigger a short squeeze despite macro-economic volatility and recent bearish sentiment surrounding the stock's valuation.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as retail investors debate the company's aggressive acquisition strategy, recent dilution, and heavy short interest against a backdrop of optimistic long-term defense and drone sector narratives. Community discussion is heavily polarized, with bulls highlighting the company's significant revenue backlog and strategic government partnerships, while bears caution against continued dilution and the stock's recent downward price trend.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

Defiance Daily Target 2x Long MSTR ETF

MSTX is trending as investors aggressively trade the leveraged ETF amid intense volatility and speculation surrounding Bitcoin's price movements and MicroStrategy's corporate treasury strategy. The community is sharply divided between those viewing these dips as strategic buying opportunities for amplified gains and others cautioning about long-term decay risks and the potential for further reverse splits.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing significant volatility driven by the closing of its TopBuild acquisition, with investors closely watching institutional activity, short interest levels, and the potential impact of share dilution. The community is actively debating the stock's long-term value and the credibility of CEO Brad Jacobs' expansion strategy amidst intense market scrutiny.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors react to the company's active 10,000-meter drilling campaign in Greenland and management's ongoing updates regarding the Tanbreez project's role in Western supply chain security. Community sentiment remains polarized, with active debate focusing on project development timelines, the strategic importance of heavy rare earths, and the impact of potential geopolitical interest from nations like Japan.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as traders debate the sustainability of the AI memory cycle, with heightened volatility fueled by the upcoming US debut of SK Hynix and high-profile bearish bets from Michael Burry. The community remains sharply divided between investors betting on long-term structural demand and those anticipating a cyclical correction amid record-setting memory production and expansion news.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is experiencing significant volatility and trading interest as investors closely monitor a high-stakes proxy fight between the board and a former CEO, while simultaneously awaiting news of a major hyperscaler anchor tenant for their Texas-based data center project. The community remains deeply divided, with some betting on a massive re-rating driven by the facility's power capacity, while others warn of significant downside risk due to ongoing governance disputes and previous failed tenant negotiations.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

Investors are actively rotating capital from AI-focused hardware and semiconductors into beaten-down software stocks as sentiment shifts toward enterprise monetization. The community is closely watching $IGV as a bellwether for this trend, with traders debating whether this momentum marks a sustainable recovery or a brief mean-reversion opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$BCTX Bullish 
 
The trial design is brilliant. Upon interim readout after 144 deaths occur, Briacell may receive FDA approval if they show 40% reduction in mortality. If they don&#39;t show 40% reduction in mortality, they may continue study and receive FDA approval if they show 30% reduction in mortality. In addition, after initial interim readout, they have opportunity to tweak study design and focus on that subgroup of patients most likely to derive benefit from the drug or comtinue trial unchanged. A lot of flexibility after initial interim readout. In addition, Briacell has specific subgroups that will be evaluated (e.g. patients in which cancer has spread to brain). This is another shot on goal that may lead to FDA approval. I&#39;m very bullish because we have several opportunities for Briacell to deliver results that may lead to FDA approval. The recent Renmark presentation provides details on this.

Justin

George

Mark

Dieu Longacre

StockTwits Web

BriaCell Therapeutics Corp

 Bullish 
 
The trial design is brilliant. Upon interim readout after 144 deaths occur, Briacell may receive FDA approval if they show 40% reduction in mortality. If they don't show 40% reduction in mortality, they may continue study and receive FDA approval if they show 30% reduction in mortality. In addition, after initial interim readout, they have opportunity to tweak study design and focus on that subgroup of patients most likely to derive benefit from the drug or comtinue trial unchanged. A lot of flexibility after initial interim readout. In addition, Briacell has specific subgroups that will be evaluated (e.g. patients in which cancer has spread to brain). This is another shot on goal that may lead to FDA approval. I'm very bullish because we have several opportunities for Briacell to deliver results that may lead to FDA approval. The recent Renmark presentation provides details on this.

@PML1  exactly. There is almost zero chance they fudge this given that the triple negative (TNBC) subgroup results are outstanding with little or no existing treatment options available .  However the TAM will be lower in the case that they will need to proceed with only 1 subgroup.

Another thing they brought up again was about prevail partners who is CRO for this trial had invested $4M back in 2024. Why would a CRO invest if they don’t see this as a breakthrough vaccine.? 

The roadshows have great info.

_gatti_

StockTwits for iOS

  exactly. There is almost zero chance they fudge this given that the triple negative (TNBC) subgroup results are outstanding with little or no existing treatment options available .  However the TAM will be lower in the case that they will need to proceed with only 1 subgroup.

Another thing they brought up again was about prevail partners who is CRO for this trial had invested $4M back in 2024. Why would a CRO invest if they don’t see this as a breakthrough vaccine.? 

The roadshows have great info.